Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826708 | 0.83 | ALDH1A1 (0.39) | ALDH1A1HPGDHSD17B10SMPD3MAPT | |
| SCHEMBL3970342 | 0.79 | KDM4E (0.52) | ALDH1A1HPGDHSD17B10SMPD3KDM4E | |
| SCHEMBL16283749 | 0.76 | SMPD3 (0.33) | SMPD3 | |
| SCHEMBL10282570 | 0.74 | L3MBTL1 (0.41) | ALDH1A1KDM4EMAPTTSHRSMN1; SMN2 | |
| SCHEMBL24163472 | 0.74 | ALDH1A1 (0.41) | ALDH1A1HPGDHSD17B10SMPD3KDM4E | |
| SCHEMBL3968151 | 0.73 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10SMPD3KDM4E | |
| SCHEMBL25151627 | 0.73 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10SMPD3KDM4E | |
| SCHEMBL3959800 | 0.73 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10SMPD3KDM4E | |
| SCHEMBL25151362 | 0.72 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10SMPD3KDM4E | |
| SCHEMBL21120068 | 0.72 | KDM5A (0.40) | ALDH1A1HPGDHSD17B10SMPD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| EP-3606926-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-02-12 | — | — | EP | disclosed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | disclosed |
| WO-2018185120-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | PIKFYVE, PI4KA, PIP4K2B | ALDH1A1 4239/4885HPGD 4093/4885HSD17B10 3489/4885 |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | BECN1, SQSTM1, TFEB | ALDH1A1 1445/4885HPGD 2348/4885HSD17B10 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.